CIPLA stock news on Anadi Algo News

For pharma, focus on companies with strong product pipelines and favorable regulatory outcomes. Maintain a bullish bias on select pharma stocks, especially those benefiting from rupee weakness or defensive buying.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

et_companies3 days ago

India raises price cap on cancer drugs to tackle shortage

This news directly impacts the profitability of oncology drug manufacturers within the Indian pharma sector, which has recently seen defensive buying and rupee weakness benefits. Regulatory signals like this are crucial for assessing the operating environment.

hold

Bullish+52.290%

5 facts SUNPHARMA

Maintain a bullish bias on Indian pharma stocks with strong oncology segments, focusing on companies that produce these specific drugs, with disciplined risk management.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

et_markets3 days ago

Never sell because you're bored': PPFAS CIO Rajeev Thakkar's 6-point guide on when to exit an investment

The pharma sector is currently seeing defensive buying and benefits from rupee weakness, as highlighted by recent rallies in stocks like Dr. Reddy's and Cipla. This makes disciplined exit strategies even more critical for investors holding these stocks after significant gains.

Neutral+16.990%

et_markets3 days ago+46.9

For pharma stocks, maintain a 'hold' bias for quality names, but be prepared to trim positions if extreme overvaluation or structural disruption (e.g., major regulatory changes or patent expirations) becomes evident, with strict stop-losses.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

Latest CIPLA Stock Coverage

Horizon Reclaim IPO opens for subscription today. Check GMP, price band and other details

hold5 facts Chemicals Manufacturing

For IPOs with strong GMP, consider applying for listing gains, but always assess the company's fundamentals and sector outlook.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

et_markets3 days ago+9.4

GenXAI Analytics shares set for listing. Here's what GMP suggests ahead of debut

et_economy4 days ago+31.9

Neutral to cautious bias for GenXAI Analytics post-listing; avoid aggressive buying on debut unless strong fundamentals emerge.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

Tieups with higher per capita income nations beneficial to all: Piyush Goyal

hold5 facts SUNPHARMA pharma

Positive for export-oriented sectors. Look for companies with strong global presence.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

et_companies4 days ago+31.9

Cancer drug prices raised 50% as NPPA acts on shortage concerns

et_markets4 days ago+16.9

Look for Indian pharma companies with strong oncology or critical care portfolios; potential for margin improvement.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

Quote of the day by Arnold Van Den Berg: "We believe that if a market is so overvalued that you can only find a few stocks to buy, you are probably better off not buying anything"

5 facts broad_market

Maintain a selective 'buy on dips' strategy for quality stocks, or increase cash holdings for future opportunities.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

livemint_markets4 days ago+31.9

The good, the bad, and the ugly of the Indian stock market: How should investors navigate it?

livemint_markets4 days ago+10.8

Look for accumulation opportunities in quality stocks across various sectors, focusing on companies with strong balance sheets and growth potential, with a long-term horizon.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (+0.8% 1d).

Vahh Chemicals share price lists at 17% premium over IPO price on BSE SME

hold5 facts pharma

Bearish bias for Vahh Chemicals in the immediate term due to lower circuit hit; caution advised for new positions.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

et_markets4 days ago+53.6

'India's AI index beat Mag-7 plus Nvidia': Hiren Ved says stop mourning FII exits and start investing smarter

5 facts Information Technology Financial Services

Maintain a bullish bias on Indian IT stocks with strong AI integration strategies; consider long positions in companies demonstrating clear AI-led innovation and efficiency gains, with a stop-loss below recent support levels.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

et_markets4 days ago+18.4

India's next decade: AI is an enabler, not a threat; investor expectations the real risk: Kailash Kulkarni

5 facts Information Technology Financial Services

For pharma, look for companies with strong R&D pipelines and diversified geographical revenue streams, considering defensive buying in times of market uncertainty.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

et_markets5 days ago+14.6

OpenAI expects to go public 'within the next year,' the Information reports

livemint_companies5 days ago+7.1

Neutral to mildly positive for Indian IT; watch for AI-related project demand.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

Asics to spin off its Onitsuka Tiger sneaker business

4 facts

N/A, as the news is not related to the pharma sector.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

et_economy5 days ago+55.9

India's bond tax exemptions set to boost foreign debt inflows and global index inclusion bid

et_markets5 days ago+29.6

Long Indian government bonds; anticipate yield compression due to increased demand.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

Physicswallah is ‘class’ apart, says DAM Capital after initiating with Buy rating. 3 reasons why

5 facts Education Technology

Maintain a watchlist of unlisted ed-tech companies and monitor news for IPO filings; consider early-stage investment opportunities if accessible, or look for indirect plays in allied sectors.|Quick check: SUNPHARMA neutral (oversold), CIPLA neutral (-0.1% 1d).

livemint_companies5 days ago+18.4

Margin play: Why Supertails is doubling down on the lucrative pet healthcare market

5 facts Animal Healthcare Retail

Consider a long-term bullish bias for Indian companies with established animal health divisions or those poised to enter the formal pet care market, focusing on companies with strong distribution networks.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_markets5 days ago+44.7

A new IPO frenzy: Why is Bharat making a beeline for bourses?

5 facts Retail Consumer Discretionary

Maintain a bullish bias on organized retail, focusing on companies with a clear strategy for 'Bharat' expansion, with a long-term investment horizon.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_markets5 days ago-41.6

Bitcoin trades 50% below all time high, below $62,000 as geopolitical uncertainty weighs on crypto sentiment

et_markets5 days ago+33.4

Consider long positions in fundamentally strong pharma stocks with good product pipelines and USFDA approvals, maintaining strict stop-losses.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

We are in Sankat Kaal, and in this Sagar Manthan, our job is to look for the next generation of winners: Saurabh Mukherjea

5 facts Manufacturing Export-Oriented Industries

Consider long positions in fundamentally strong pharma exporters, focusing on companies with robust R&D and diversified product portfolios, with strict risk management.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

livemint_markets5 days ago+40.9

CMR Green Technologies share price makes a bumper debut, stock opens with 40% premium at ₹268 apiece on NSE

sell5 facts Metals & Mining Recycling

Look for opportunities in companies aligned with green technologies, recycling, or industrial manufacturing, with a bias towards strong fundamentals and clear growth prospects.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

livemint_companies6 days ago+18.4

Dharana Capital buys 12-14% stake worth ₹225 crore in Mygate

5 facts Technology Real Estate

Maintain a positive bias on Indian tech and digital services companies, especially those with strong growth potential and clear market differentiation. Consider long positions in companies benefiting from digital transformation trends.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_companies6 days ago+29.7

Duty relief may be extended for petrochemical inputs for pharma

livemint_markets6 days ago+18.4

Positive sentiment for pharma stocks, especially those with significant petrochemical input reliance.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

Nuvalent shares surge 39% to record high as GSK agrees to $10.6 billion acquisition deal

sell5 facts SUNPHARMA CIPLA Pharmaceuticals Healthcare

Maintain a bullish bias on Indian pharma stocks with robust oncology portfolios; look for entry points on minor corrections with strict stop-losses.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_economy6 days ago+37.2

India eyes more FDI, speed up divestment, asset monetisation as economy faces external risks

et_markets6 days ago+40.9

Positive bias for sectors attracting FDI and potential PSU divestment candidates.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

CRISIL's Dharmakirti Joshi gives India a 7 out of 10 on growth durability; says private capex has the money but not the will

5 facts Capital Goods Infrastructure

Maintain a neutral to slightly positive bias on pharma, focusing on companies with strong product pipelines and export potential, but be mindful of broader market shifts towards cyclical growth.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_economy6 days ago+52.2

India scrapping tax for foreign investors in govt bonds aimed at inclusion in Bloomberg index, govt official says

5 facts Financial Services Government Bonds

Look for opportunities in banking and financial stocks that benefit from lower interest rates and increased foreign capital inflows, with a bullish bias.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_markets6 days ago+44.7

FPI inflows into FAR securities rise by Rs 8,795 cr after govt tax exemption move

5 facts Financial Services Government Bonds

Maintain a bullish bias on financial stocks, particularly those with strong balance sheets, as improved liquidity and a stable Rupee create a favorable operating environment. Consider long positions with a stop-loss below key support levels.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

livemint_companies6 days ago+40.9

SBI steps in with $1-billion funding for Sun Pharma’s Organon deal

sell5 facts SUNPHARMA Pharmaceuticals Banking

Maintain a bullish bias on quality pharma stocks, particularly those with clear growth strategies and strong financial backing. Look for entry points on minor pullbacks.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA bearish bias (-0.9% 1d).

et_companies6 days ago-49.8

Indian cancer patients battle shortage of key drugs as platinum costs surge

5 facts Pharmaceuticals Healthcare

Maintain a cautious to bearish bias on pharma stocks heavily reliant on imported APIs, especially those with significant oncology portfolios, and consider short-term hedging strategies.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

livemint_markets6 days ago+10.2

Genxai Analytics IPO Day 3: GMP signals 5% listing gains; check subscription status and other details

5 facts Financial Services Information Technology

For upcoming IPOs, consider applying for those with strong subscription numbers and positive GMP, but always exercise risk management due to inherent volatility.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

et_economy6 days ago+44

Assam CM Himanta Biswa Sarma meets 'Team Europe' delegation to boost trade, investment linkages

hold5 facts Semiconductors Pharmaceuticals

Look for Indian pharma companies with strong export potential to Europe or those with R&D capabilities in green energy and semiconductor materials, with a long-term bullish bias.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

et_companies6 days ago+47.7

Customers will feast as Zepto to pour fuel into quick commerce fire

5 facts E-commerce Logistics

Maintain a cautious to bearish bias on listed quick commerce-related stocks, anticipating increased operational costs and potential margin compression.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

et_economy6 days ago-49.8

Indian employers turn cautious for July-September quarter amid global uncertainties: Report

5 facts utilities finance

Maintain a cautious bias; consider reducing exposure to cyclical stocks and increasing allocation to defensive sectors.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

et_companies7 days ago+6.5

India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide sales

et_markets7 days ago+10.2

Be cautious with pharma companies heavily reliant on the anti-obesity segment. Favor companies with diversified portfolios or strong market differentiation.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss market

5 facts Pharmaceuticals Healthcare

Maintain a neutral to slightly cautious bias on Indian pharma stocks with significant diabetes portfolios, as global competition intensifies. Focus on companies with robust R&D pipelines and diversified product portfolios.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

livemint_markets7 days ago-34.8

UHM Vacation IPO Day 3: GMP plunges sharply! Here's subscription status, price band and other details

5 facts Travel & Tourism IPO Market

Maintain a cautious stance on new IPOs in the travel tech space, prioritizing companies with strong fundamentals and reasonable valuations over speculative plays.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (-1.1% 1d).

livemint_markets7 days ago+3.4

Do you know how an IPO works in India? Here's a step-by-step guide

5 facts Financial Services

For pharma, continue to monitor USFDA approvals, new drug launches, and currency fluctuations (INR weakness is positive).|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (+0.0% 1d).

et_markets7 days ago+59.6

Power entering a 10-year supercycle? Elara Capital's Rupesh D Sankhe reveals the best stocks to own

5 facts Power Generation Power Transmission

Maintain a bullish bias on the power sector; consider long positions in established power generation, transmission, and equipment manufacturing companies, with a focus on long-term holding.|Quick check: SUNPHARMA bearish bias (oversold), CIPLA neutral (+0.0% 1d).

livemint_markets11 days ago-58.7

Nifty 50 EPS cuts: Cipla, L&T, Adani Enterprises, Adani Ports among top downgrades in May

hold5 facts CIPLA ADANIENT ADANIPORTS Pharmaceuticals Infrastructure

Maintain a cautious stance on Nifty 50 large-caps; consider reducing exposure to companies with significant EPS downgrades and look for defensive sectors or high-quality stocks with stable earnings visibility.|Quick check: CIPLA bearish bias (-0.9% 1d), ADANIENT neutral (overbought).

et_companies17 days ago+55.7

Molecule glue drugs shake up cancer care, draw big money

hold5 facts CIPLA Pharmaceuticals Biotechnology

Maintain a bullish bias on Indian pharma stocks with strong R&D and oncology focus, looking for dips to accumulate.|Quick check: CIPLA neutral (overbought), SUNPHARMA neutral (oversold).

et_companies18 days ago+56.1

Cipla is aiming for 40-50 global product filings in three years, says MD Achin Gupta

hold5 facts CIPLA pharmaceuticals

Long-term bullish on CIPLA. Look for entry points on any market corrections.|Quick check: CIPLA neutral (overbought), MARUTI neutral (+0.0% 1d).

et_markets25 days ago+55.8

IT a tactical buy; Devarsh Vakil reveals 5 sectors worth buying as markets turn volatile

hold5 facts TCS INFY WIPRO Information Technology Power

Long positions in fundamentally strong banking stocks are favored, with a bias towards those demonstrating robust credit growth and improving asset quality.|Quick check: TCS bearish bias (-0.3% 1d), INFY bullish bias (-0.4% 1d).

et_companies26 days ago-18.3

No cosmetic job with jabs, warns drug regulator CDSCO

hold5 facts DRL CIPLA pharma

Cautious to bearish bias for pharma companies with aesthetic product exposure; monitor regulatory updates.|Quick check: DRL neutral, CIPLA bullish bias (-0.6% 1d).

et_companies28 days ago-27.2

Rising input costs, export slump take a toll on drug companies' health

buy5 facts SUNPHARMA DRL CIPLA pharma

Bearish outlook for the pharmaceutical sector; potential for margin contraction.|Quick check: SUNPHARMA bullish bias (+1.4% 1d), DRL neutral.

livemint_marketsabout 1 month ago+78.2

Top Gainers & Losers on May 14: NLC India, Cipla, Bharti Airtel, Vedanta, MCX, BSE, Berger Paints among top gainers

buy5 facts NLCINDIA CIPLA BHARTIARTL Pharmaceuticals Metals & Mining

Consider a long bias in select pharma and metal stocks, focusing on companies with strong fundamentals and positive news flow, while maintaining strict stop-losses.|Quick check: NLCINDIA bullish bias (overbought), CIPLA bullish bias (+7.7% 1d).

et_marketsabout 1 month ago+56.6

Cipla shares rally 8% despite 55% YoY slump in Q4 profit. Why Citi, Nuvama, other brokerages hiked target

hold5 facts CIPLA Pharmaceuticals

Maintain a bullish bias on Cipla, looking for entry points on minor pullbacks, with strict stop-losses below recent support levels.|Quick check: CIPLA bullish bias (+2.8% 1d), MARUTI bearish bias (-0.6% 1d).

et_marketsabout 1 month ago+51.4

Markets choppy, inflation looming: Pashupati Advani on what should investors do now

hold5 facts SUNPHARMA DRL Infrastructure Pharmaceuticals

Consider long positions in fundamentally strong pharma companies with robust pipelines and good regulatory standing, maintaining strict stop-losses.|Quick check: SUNPHARMA bullish bias (-1.1% 1d), DRL neutral.

livemint_companiesabout 1 month ago+67.1

Cipla bets on fast-growing biosimilars market, to steadily add products: CEO

buy5 facts CIPLA DRL BIOCON Pharmaceuticals Healthcare

Maintain a bullish bias on Indian pharma stocks with strong R&D and biosimilar pipelines, with a focus on companies demonstrating successful product launches and regulatory approvals.|Quick check: CIPLA bullish bias (+2.8% 1d), DRL neutral.

et_companiesabout 1 month ago-38.9

Cipla Q4 profit drops 55% to Rs 555 crore; board recommends Rs 13 dividend

buy5 facts CIPLA Pharmaceuticals

Maintain a cautious bias on pharma stocks; look for strong fundamental performance and clear regulatory pathways before initiating long positions.|Quick check: CIPLA bullish bias (+2.8% 1d), SUNPHARMA bullish bias (-1.1% 1d).

et_marketsabout 1 month ago-57

Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividend

hold5 facts CIPLA Pharmaceuticals

Maintain a cautious bias on Cipla (CIPLA) and potentially other large-cap pharma stocks; consider short positions or hedging strategies if key support levels are breached.|Quick check: CIPLA neutral (+0.0% 1d), TATASTEEL neutral (-0.2% 1d).

livemint_marketsabout 1 month ago-58.7

Cipla Q4 Results: Net profit falls 55% to ₹554.64 crore, revenue drops 3% YoY; declares dividend of ₹13 per share

sell5 facts CIPLA Pharmaceuticals

Given the negative earnings, a short-term bearish bias for Cipla (CIPLA) is warranted. Traders should look for confirmation of downward momentum and manage risk with appropriate stop-losses.|Quick check: CIPLA bearish bias (+0.0% 1d), MARUTI bearish bias (-2.3% 1d).

livemint_marketsabout 1 month ago+43.5

Q4 results 2026: Bharti Airtel to Tata Motors among companies to declare Q4 results today; check full list here

sell5 facts BHARTIARTL TATAMOTORS TVSMOTOR Telecommunications Automobiles

For auto stocks, look for strong volume growth and margin resilience; trade with a bias towards companies showing robust EV transition plans, but be disciplined with stop-losses given recent volatility.|Quick check: BHARTIARTL bearish bias (oversold), TATAMOTORS bearish bias (-2.2% 1d).

et_marketsabout 1 month ago+55.6

Cipla Share Price Live Updates: Cipla's Strong Monthly Returns

hold4 facts CIPLA pharma

Consider a bullish bias for CIPLA; look for entry points on minor pullbacks or breakout confirmations.|Quick check: CIPLA neutral (overbought), NIFTY neutral.

livemint_marketsabout 1 month ago+62.2

Q4 results 2026: Bharti Airtel to HAL among companies to declare Q4 results next week; full list here

buy5 facts BHARTIARTL HAL TATAMOTORS Telecommunications Defense

Look for long opportunities in auto stocks that beat expectations on volumes and profitability, with a stop-loss below key support levels.|Quick check: BHARTIARTL neutral (-0.0% 1d), HAL bullish bias (overbought).

livemint_marketsabout 1 month ago+59

Stock market today: Gift Nifty hints gap-down start; US-Iran war, oil to gold, silver rates — 8 stocks to buy or sell

hold5 facts BANDHANBNK INDIGO Banking Aviation

Maintain a cautious stance on banking stocks; consider short-term trades based on individual stock news and technical levels, with a bias towards defensive plays.|Quick check: BANDHANBNK bullish bias (overbought), INDIGO bearish bias (oversold).

et_companiesabout 1 month ago+42

Two separate venues for pharma industry expos in Delhi-NCR

buy5 facts SUNPHARMA DRREDDY CIPLA pharma healthcare

Maintain a bullish bias on Indian pharmaceutical stocks, especially those with strong API and formulation capabilities.|Quick check: SUNPHARMA bullish bias (+2.1% 1d), DRREDDY bullish bias (overbought).

et_marketsabout 2 months ago-61.2

Why is market falling today? Sensex slumps over 900 points, Nifty below 23,900; 7 key factors

hold5 facts NIFTY SENSEX Equity Market Oil & Gas

Consider a long bias in select pharma stocks with strong fundamentals and positive news flow, while maintaining strict stop-losses due to overall market volatility.|Quick check: NIFTY neutral, SENSEX neutral.

livemint_marketsabout 2 months ago+43.2

Buy or sell: Gift Nifty down after escalation in US-Iran war, Vaishali Parekh recommends three stocks to buy today

buy5 facts CIPLA KFINTECH broad_market pharma

Cautious approach due to geopolitical risk. Consider recommended stocks for relative strength or defensive plays.|Quick check: CIPLA bullish bias (overbought), KFINTECH neutral (+1.8% 1d).

livemint_marketsabout 2 months ago+57.8

Cohance Lifesciences share price surges 37% in two days on appointment of new CEO

buy5 facts CIPLA Pharmaceuticals Healthcare

For Cohance Lifesciences, the immediate bias is bullish, but traders should consider the sharp rally and potential for short-term profit booking. A disciplined approach with stop-losses is crucial.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.

et_marketsabout 2 months ago+71.8

Coherence Lifesciences shares rocket 43% in just 2 trading sessions. Here’s what is fuelling the surge

buy5 facts COHANCE CIPLA pharmaceuticals

Long bias for Cohance Lifesciences; look for consolidation after the initial surge for potential entry points.|Quick check: COHANCE bullish bias (overbought), CIPLA bullish bias (overbought).

et_economyabout 2 months ago+63

India–New Zealand sign 'once-in-a-generation' FTA

buy5 facts DRL Textiles Leather

Long bias for Indian pharma stocks with strong export capabilities; maintain strict stop-losses given general market volatility.|Quick check: DRL neutral, CIPLA bullish bias (overbought).

et_economyabout 2 months ago+63

India-New Zealand FTA to give major boost to exports: Experts

buy5 facts DRL CIPLA Manufacturing Pharmaceuticals

Consider a long bias on established Indian pharmaceutical companies with strong export capabilities, focusing on those with diverse product portfolios.|Quick check: DRL neutral, CIPLA bullish bias (overbought).

livemint_marketsabout 2 months ago+76.6

Top Gainers & Losers on April 27: Sun Pharma, Varun Beverages, Suzlon Energy, Anant Raj among top gainers

buy5 facts SUNPHARMA VBL SUZLON Information Technology Pharmaceuticals

Consider a bullish bias for select pharma stocks with strong pipelines and export exposure; maintain strict stop-losses below recent support levels.|Quick check: SUNPHARMA bullish bias (+7.0% 1d), VBL bullish bias (overbought).

et_companiesabout 2 months ago+55.8

Sun Pharma: How a small Kolkata trader became a global buyout artist

sell5 facts SUNPHARMA DRL CIPLA Pharmaceuticals

Maintain a bullish bias on SUNPHARMA, but monitor for potential integration challenges and debt implications post-acquisition. Consider long positions with defined risk management.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.

et_marketsabout 2 months ago+58.8

Cohance Lifesciences shares skyrocket 20% on hiring former Cipla CEO Umang Vohra

hold5 facts CIPLA Pharmaceuticals Healthcare

For Cohance Lifesciences, maintain a bullish bias, but set clear stop-losses given the sharp initial move. Look for consolidation or further positive news for entry points.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.

et_companiesabout 2 months ago+57.5

ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till date

sell5 facts SUNPHARMA DRL LUPIN Pharmaceuticals

Maintain a bullish bias on large-cap Indian pharma stocks, particularly those with strong balance sheets and global ambitions, with a focus on M&A-driven growth. Risk discipline is crucial given the high debt component in such large deals.|Quick check: SUNPHARMA bearish bias (-3.6% 1d), DRL neutral.

et_marketsabout 2 months ago-54

Dalal Street Week Ahead: Nifty’s next big move hinges on support test; volatility set to stay high

hold5 facts NIFTY DRL NATCOPHARM Equity Market Pharmaceuticals

Consider a cautious, range-bound trading strategy for the Nifty, with a bearish bias if 23,800 is breached. Look for opportunities in defensive pharma stocks on dips, but with strict stop-losses.|Quick check: NIFTY neutral, DRL neutral.

et_marketsabout 2 months ago+46.9

Cipla among 6 stocks flashing bullish signals, hinting at a possible uptrend

buy5 facts CIPLA broad_market

Consider long positions in Cipla and other identified stocks, with confirmation from volume and other indicators.|Quick check: CIPLA bullish bias (overbought), NIFTY neutral.

livemint_marketsabout 2 months ago+34

Stocks to watch: Infosys, Cyient, Adani Energy, RIL, LTIMindtree, among top shares in focus today

sell5 facts INFY CYIENT ADANIENT Information Technology Oil & Gas

Consider a long bias in fundamentally strong pharma stocks, focusing on those with positive regulatory signals or robust product pipelines, with strict stop-losses.|Quick check: INFY bearish bias (-3.0% 1d), CYIENT neutral (-2.7% 1d).

et_companiesabout 2 months ago+56.6

Cipla gets USFDA nod for generic respiratory issues treatment inhalation aerosol

hold5 facts CIPLA Pharmaceuticals

Maintain a bullish bias on Cipla (CIPLA) with a focus on volume and price action post-announcement, setting clear stop-losses.|Quick check: CIPLA bullish bias (+0.5% 1d), SUNPHARMA bearish bias (+0.1% 1d).

et_companiesabout 2 months ago-31.8

Alkem Labs CEO Vikas Gupta may exit company

buy5 facts ALKEM CIPLA Pharmaceuticals

Maintain a bearish bias on ALKEM in the short term, with a focus on price action around key support levels; consider a stop-loss above recent highs if taking a short position.|Quick check: ALKEM bullish bias (overbought), CIPLA neutral (+0.4% 1d).

livemint_markets2 months ago-45

US sales may drag pharma companies’ Q4, even as India holds up

hold3 facts CIPLA DRREDDY ZYDUSLIFE Pharmaceuticals Healthcare

Market has likely priced this in post Q4 results; prefer India-focused pharma (Mankind, JB Chem) over US-heavy names like Cipla, DRREDDY, ZYDUSLIFE on rallies.

et_economy2 months ago+30

India Inc ramps up exports as Iran ceasefire reopens Middle East trade

hold4 facts CIPLA DRREDDY SUNPHARMA Pharmaceuticals Packaged Foods

Market has likely priced in the headline already; only add to pharma/FMCG exports on fresh evidence of order growth, margin expansion and customs/export volume acceleration, else stay selective.

et_companies2 months ago+18

Israel-Iran war: India flags crunch in key pharma solvents used for life-saving drugs; govt moves to stabilise supply

hold4 facts DRREDDY SUNPHARMA CIPLA Pharmaceuticals Specialty Chemicals

Market has likely priced this in; wait for official feedstock-allocation updates, and only add selective long bias in quality large-cap pharma on confirmation of normalized supply, with tight stop discipline on any renewed input warning.

et_companies2 months ago+60

Comm secy asks pharma sector to cut dependence on imported raw materials

hold4 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Chemicals

Market has likely priced in the initial sentiment; however, monitor policy developments and investment announcements in API manufacturing for long-term bullish plays on domestic pharma and chemical companies.

et_companies2 months ago+60

Work on reducing import dependence for raw materials: Commerce Secretary Rajesh Agrawal to pharma industry

sell5 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Chemicals

Market has likely priced this in, but long-term investors should consider Indian pharma stocks with strong domestic manufacturing and R&D capabilities for sustained growth.

et_companies2 months ago+60

Lalitpur Pharma Park gets export push as UPSIDA, JNPA sign pact

sell4 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Logistics

Market has likely priced this in given the article age; however, monitor pharma and logistics stocks for long-term growth potential from improved export infrastructure.

et_companies2 months ago+75

India’s pharma exports stay resilient amid global headwinds, near $29 billion mark

sell5 facts SUNPHARMA DRL CIPLA Pharmaceuticals Healthcare

Consider long positions in established Indian pharmaceutical exporters, as the sector shows sustained growth despite global headwinds.

et_companies2 months ago+40

Govt orders safety review of popular weight-loss drugs amid rising demand

sell4 facts SUNPHARMA DRREDDY LUPIN Pharmaceuticals Healthcare

Monitor pharmaceutical stocks with exposure to weight-loss drugs for potential short-term volatility due to regulatory uncertainty.

et_companies2 months ago+70

AI in Pharma: How India's Drug Giants Are Betting Big on Artificial Intelligence

sell3 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Information Technology

Focus on large-cap Indian pharma companies and IT service providers with strong AI capabilities, as they are poised for long-term growth from this technological shift.

et_companies2 months ago+20

India largely shielded from US tariffs on patented drugs due to generic export strength: GTRI

sell5 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals

Maintain a neutral stance on major Indian generic pharma stocks, but monitor for any policy shifts that could extend US tariffs to generics.

livemint_markets2 months ago+60

Sun Pharma share price in focus on Monday after Trump's tariff announcement

sell4 facts SUNPHARMA DRREDDY LUPIN Pharmaceuticals

Given the article's age, the market has likely priced in initial reactions; however, monitor US trade policy developments for lingering effects on Indian pharma exporters.

et_markets2 months ago-60

Pharma calls in sick after Trump’s 100% tariff threat

sell3 facts SUNPHARMA DRL CIPLA Pharmaceuticals

Given the article's age, the immediate market reaction has passed, but traders should monitor US political developments and their potential impact on Indian pharma export-oriented companies.

et_companies2 months ago-40

Indian pharma sector faces supply risk amid West Asia conflict despite duty waiver

sell5 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Chemicals

Maintain a cautious stance on Indian pharma stocks due to persistent supply chain risks, despite government intervention.

et_economy2 months ago+40

Several measures announced to cushion exporters from Gulf conflict impact: DGFT

sell4 facts PIDILITIND TITAN KRBL Gems & Jewellery Food Processing

Market has likely priced this in, but watch for specific company announcements on benefiting from these measures; positive for export-oriented stocks in affected sectors.

et_markets2 months ago-70

Tariff threat ain't over yet! Sun Pharma, other pharma stocks plunge up to 6%

sell4 facts SUNPHARMA DRL LUPIN Pharmaceuticals

Given the article's age, the immediate market reaction has likely occurred; however, maintain a cautious stance on Indian pharma stocks with high US exposure, as policy uncertainty could persist.

et_companies3 months ago-60

China pulls ahead in biologics race, forcing Indian drugmakers to rethink strategy

sell4 facts DRL SUNPHARMA CIPLA Pharmaceuticals Biotechnology

Bearish for Indian pharma stocks with significant biologics exposure; monitor strategic shifts and R&D investments.

sell4 facts LUPIN DRREDDY SUNPHARMA Pharmaceuticals Healthcare

Mint Explainer: What the weight-loss drug frenzy means for pharma sector and for you

Monitor Indian pharmaceutical companies with strong R&D and manufacturing capabilities for generic semaglutide, as initial price wars may give way to volume-driven growth.

sell5 facts LUPIN DRREDDY SUNPHARMA Pharmaceuticals Healthcare

Govt of India cracks down on GLP-1 drugs: Safety first amid weight-loss hype

Monitor Indian pharmaceutical companies with significant GLP-1 drug pipelines for potential short-term revenue adjustments due to increased regulatory friction.

sell5 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Chemicals

'Allocate key chemicals to avert drug shortages', says Pharmexcil amid West Asia war

Monitor government actions on chemical allocation; potential for short-term volatility in pharma stocks, but long-term impact depends on resolution.

livemint_companies3 months ago-60

Novo Nordisk slashes Ozempic, Wegovy prices as generic competition heats up

hold3 facts LUPIN SUNPHARMA DRREDDY Pharmaceuticals Healthcare

Bearish for Indian pharma companies with significant diabetes/obesity portfolios; consider reducing exposure or shorting specific names.

et_companies3 months ago-70

Novo Nordisk cuts Ozempic and Wegovy prices by up to 48% as GLP-1 competition intensifies in India

sell4 facts LUPIN DRL SUNPHARMA Pharmaceuticals Healthcare

Bearish for Indian pharma companies with GLP-1 development pipelines or significant diabetes portfolios; consider reducing exposure or shorting specific names.

et_economy3 months ago-60

Non-violation complaints under WTO's TRIPS agreement: An explainer

sell4 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals Information Technology

Market has likely priced this in given the article age; however, monitor for specific company announcements regarding IP disputes, especially in pharma and IT.

et_markets3 months ago+70

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka

sell5 facts AJANTPHARM SUNPHARMA LUPIN Pharmaceuticals Healthcare

Consider accumulating Indian pharmaceutical stocks with strong metabolic therapy pipelines, as the GLP-1 market shift presents a significant long-term growth opportunity.

et_companies3 months ago+30

Regulator steps up oversight of GLP-1 drug distribution chain

hold4 facts LUPIN SUNPHARMA DRREDDY Pharmaceuticals Healthcare

Market has likely priced this in; monitor major pharma companies for any specific announcements regarding GLP-1 drug compliance or market strategy shifts.

hold6 facts APOLLOHOSP DRL LUPIN Healthcare Pharmaceuticals

India’s urban health alarm: One in five at early heart risk, 25% face respiratory threat

Bullish for Indian healthcare and pharmaceutical stocks; consider long-term positions in hospital chains, diagnostic labs, and pharma companies focused on lifestyle diseases.

buy3 facts DRREDDY LUPIN SUNPHARMA Pharmaceuticals

Novo Nordisk sues Dr. Reddy’s over Ozempic trademark

Bearish for Dr. Reddy's in the near term due to legal overhang; watch for similar actions against other generic players entering the weight-loss drug market.

et_markets3 months ago+60

War, falling markets, and a two-year window: Why Vikas Khemani is buying banks, aviation, and pharma right now

sell4 facts HDFCBANK ICICIBANK INDUSINDBK Banking Aviation

Consider accumulating quality stocks in banking, aviation, and pharma with a 2-3 year investment horizon, as geopolitical risks subside and market sentiment improves.

hold5 facts SUNPHARMA DRL CIPLA Pharmaceuticals Healthcare

India tightens grip on GLP-1 supply chain amid misuse concerns, expands crackdown on unapproved drugs

Monitor pharmaceutical companies for increased compliance costs and potential shifts in product portfolios due to stricter drug sale regulations.

et_markets3 months ago+70

Rs 12,000 crore magic pill race begins to shrink India's pot bellies. Which pharma stocks will win GLP-1 war?

sell5 facts DRL SUNPHARMA LUPIN Pharmaceuticals Healthcare

Consider accumulating Indian pharmaceutical stocks with strong R&D and manufacturing capabilities, as they are poised to benefit from the expanding GLP-1 market.

hold4 facts DRREDDY SUNPHARMA LUPIN Pharmaceuticals Healthcare

Indian drugmakers flood market with cheaper versions of Novo's Ozempic, Wegovy

Bullish for Indian generic pharma companies; consider long positions in major players with strong domestic presence.

et_companies3 months ago+65

Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weight

hold5 facts SUNPHARMA DRREDDY LUPIN Pharmaceuticals

Consider long positions in Indian pharmaceutical companies with strong generic pipelines, as the obesity drug market offers significant growth potential.

et_companies3 months ago+75

A blockbuster unleashed: What happens when a big fat business explodes?

hold4 facts DRREDDY SUNPHARMA LUPIN Pharmaceuticals Healthcare

Bullish for Indian pharmaceutical companies; consider long positions in major generic drug manufacturers with strong R&D and manufacturing capabilities.

hold4 facts DRL LUPIN SUNPHARMA Pharmaceuticals Healthcare

Dr. Reddy’s Lab launches India’s first DCGI-approved Semaglutide injection for Type 2 Diabetes

Consider a long position in Dr. Reddy's Laboratories (DRL) on dips, as this launch provides a significant growth driver in the diabetes segment.

buy4 facts SUNPHARMA DRREDDY LUPIN Pharmaceuticals Healthcare

Novo to track generic surge as semaglutide goes off patent

Traders should monitor Indian pharmaceutical companies for their generic semaglutide launch plans and assess potential pricing strategies, as increased competition could compress margins.

hold3 facts EMCURE DRREDDY SUNPHARMA Pharmaceuticals

Emcure betting on innovator edge in crowded weight-loss drug market

Monitor Q1/Q2 FY27 results of major Indian pharma players for early indications of market share and pricing power in the generic Semaglutide segment.

sell3 facts SUNPHARMA DRREDDY CIPLA Pharmaceuticals

India regulator asks states to implement uniform drug licensing norms to end quality gaps

Consider long positions in large-cap, compliant pharmaceutical companies as regulatory standardization reduces operational risks and improves market access.

et_markets3 months ago-60

Cipla, GSPL among 6 stocks that hit 52-week lows; slip up to 24% in a month

sell4 facts CIPLA GSPL Pharmaceuticals Oil & Gas

Given the article's age, the market has likely priced in these 52-week lows; traders should now look for signs of stabilization or reversal before considering entry, or further weakness for shorting opportunities.